GENEURO SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.43 EUR | -1.04% |
|
-4.67% | +31.19% |
| Mar. 20 | Geneuro SA Announces Appointments of Board of Directors | CI |
| Feb. 02 | GeNeuro: share price falls after private placement | CF |
| Sales 2023 * | - | Sales 2024 * | 28.2M 30.04M | Capitalization | 42.32M 45.08M |
|---|---|---|---|---|---|
| Net income 2023 * | -11M -11.72M | Net income 2024 * | 1M 1.07M | EV / Sales 2023 * | - |
| Net Debt 2023 * | 13M 13.85M | Net Debt 2024 * | 7.9M 8.42M | EV / Sales 2024 * | 1.78 x |
| P/E ratio 2023 * |
-3.33
x | P/E ratio 2024 * |
47.7
x | Employees | 19 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 73.47% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.04% | ||
| 1 week | -4.67% | ||
| Current month | +3.62% | ||
| 1 month | +15.32% | ||
| 3 months | +11.28% | ||
| 6 months | +23.81% | ||
| Current year | +31.19% |
1 week
1.40
1.48
1 month
1.221.53
Current year
1.051.70
1 year
0.942.00
3 years
0.945.50
5 years
0.946.28
10 years
0.9413.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 05-12-31 | |
Hervé Perron
FOU | Founder | 66 | 05-12-31 |
Miguel Payró
DFI | Director of Finance/CFO | 62 | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-05-26 | |
Michel Dubois
BRD | Director/Board Member | 81 | 08-07-15 |
Gordon Francis
BRD | Director/Board Member | 75 | 15-03-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.43 | -1.04% | 3,373 |
| 24-04-18 | 1.445 | -0.34% | 2,422 |
| 24-04-17 | 1.45 | +0.69% | 4,519 |
| 24-04-16 | 1.44 | -1.37% | 5,007 |
| 24-04-15 | 1.46 | -1.02% | 3,728 |
Real-time Euronext Paris, April 19, 2024 at 11:12 am EDT
More quotes
GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Calendar
2024-04-28
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.43
EUR
Average target price
4
EUR
Spread / Average Target
+179.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.19% | 45.6M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- GNRO Stock
